We have employed random mutagenesis and phage display to improve the steroid-specificity of an anti-17β-estradiol Fab fragment. The V H domain was mutated using errorprone PCR; the mutation rate was controlled by adjusting the number of effective duplications. A phage library of 2 ⍥ 10 6 independent mutants was generated, each mutant containing on average 2-4 amino acid changes. We selected for decreased testosterone (TES) cross-reactivity by adding a large excess TES as a competitor to the panning reactions. After four panning rounds, the cross-reactivities of the individual mutant clones ranged from 19 to 4%, showing up to 20-fold improvement over the original value (78%). Estradiol affinities were mainly unchanged. Sequencing of the V H regions revealed two hot spots, one located around Ser32 in CDR1 and the other around Thr52 A in CDR2, while no mutations were found in CDR3. Although most clones had multiple mutations, it was possible to deduce the residues relevant to the improved specificity by comparing the sequences and binding data of the mutants. We demonstrated that controlled error-prone PCR mutagenesis is a rapid method to identify such key residues, lending itself to the scanning of 'lead' positions for further mutagenesis by other methods.
Introduction
Monoclonal antibodies (Mabs) are widely used in clinical in vitro diagnostics owing to their ability to specifically recognize molecules from complex biological samples. However, there are analytes for which it is difficult to find specific enough Mabs. A classic case is estradiol (E2), the principal estrogen hormone. E2 belongs to a group of structurally similar sex steroids which differ only by the number and types of substitutions at a few positions around the common steroid nucleus and by the degree of saturation of the bonds between the ring carbons, leading to slight conformational changes in the rigid skeleton. The currently available anti-E2 Mabs usually cross-react with either the A-or D-ring analogs of the steroid, suggestive of partial lack of shape complementarity between the hapten and the binding site. The sub-optimal antibodies produced by the mouse immune system could possibly be reshaped by antibody engineering (reviewed by Winter et al., 1994) , especially if coupled with the phage display technology, originally discovered by Smith (1985) . Recently, a human anti-estradiol antibody was isolated from a semi-synthetic, unimmunized phage library (Pope et al., 1996) . The reported specificity profile was promising (although not comprehensive), indicating that the human germline diversity might offer different structural solutions to steroid binding and perhaps complement the mouse repertoire as a starting point for the engineering of ideal E2 binders.
We have previously cloned the antibody genes of three anti-E2 hybridoma cell lines and expressed them in Escherichia coli as Fab fragments (Pajunen et al., 1997) . One of the antibodies, 57-2, shows excellent specificity for the D ring of E2 (Figure 2 ), having less than 0.2% cross-reactivity with the clinically relevant D ring derivatives, estriol (16α-OH) and estrone (17-keto). However, it has a high (77%) cross-reactivity with testosterone (TES). The structures of E2 and TES are otherwise identical except for the A ring ( Figure 2 ). The A ring of TES is nonaromatic, the C3 substituent is a keto instead of a hydroxyl group and the C10 has a β-methyl substituent (C19) that is missing from estradiol. The high cross-reactivity to TES suggests that the hapten binding site fails to form specific contacts with the steroid A ring. As the Mab 57-2 was raised by immunizing mice with estradiol conjugated to BSA through a linker at position C6 (Pajunen et al. 1997) , there is no compelling reason for the positions C3 and C10 to be exposed to the solvent. Consequently, there was a case for improving the A ring recognition by protein engineering.
In the present study, we aimed at decreasing the TES crossreactivity of the anti-estradiol Fab 57-2 by random mutagenesis of the V H domain, followed by phage display selection. Similar studies have previously shown that it is possible to find improved mutants from whole domain random libraries even if they cover only a fraction of the potential diversity (Hawkins et al. 1992 (Hawkins et al. , 1993 . In the random mutagenesis and panning of the phage-displayed anti-lysozyme scFv D1.3, Hawkins et al. (1993) found several moderately improved affinity mutations. However, none was located in the contact interface, demonstrating the difficulty to predict beneficial mutations even when the three-dimensional structure of the antibody-antigen complex is known. As we had no structural data (actual or modelled) on Mab 57-2, we prepared a random mutant library of a whole domain, using error-prone PCR mutagenesis. In order to increase the reproducibility of this mutagenesis method originally described by Leung et al. (1989) and later modified by Cadwell and Joyce (1992) , we experimentally determined the mutation rate per duplication cycle, which allowed for the predictable control of the overall mutation rate by adjusting the amount of the initial template in the PCR. To isolate mutants with decreased cross-reactivity to TES, we added TES as a competing ligand to the panning reaction; the effect of the competitor concentration on the dynamics of the panning process will be discussed. Finally, we will discuss the scope and reach of the whole domain random library approach in the engineering of antibody specificity.
Materials and methods

Plasmids, phage and cells and media
The Fd and kappa chains of the monoclonal 17β-estradiol antibody 57-2 (Pajunen et al., 1997) were cloned into the phage display vector pComb3 (Barbas et al., 1991) using the XhoI and SpeI sites for the insertion of the Fd chain and the SacI and XbaI sites for the insertion of the kappa chain, respectively. The resulting plasmid ( Figure 1A ) is here termed 57-2/pComb3. Phagemid rescue was carried out with the helper phage VCS M13 (kan r , Stratagene). The host strain was Escherichia coli endA1, gyrA96, hsdR17, supE44, relA1, lac, [FЈ proAB, lacI q Z∆M15, Tn10 (tet r )], Stratagene}. The culture media (SB, SOC) and LA plates were prepared as described in Sambrook et al. (1989) .
Error-prone PCR
The error-prone PCR conditions were adopted from Leung et al. (1989) and Cadwell and Joyce (1992) . A preliminary range finding experiment was performed as follows. The plasmid 57-2/pComb3 was linearized by XbaI digestion and 10 pg (3 amol) was used as template in the PCR reaction. The reaction mix (100 µl) contained 10 mM Tris-HCl (pH 9.0), 50 mM KCl, 7 mM MgCl 2 , 0.5 mM MnCl 2 , 1 mM dCTP and dTTP, 0.2 mM dGTP and dATP, 0.01% (w/v) gelatin, 0.1% (v/v) Triton X-100, 5 U Taq polymerase (Promega) and 0.3 µM each of the primers WO265, CAT GTC TCG AGT CTG GAC CTG AAC TG and WO267, CTA GAC TAG TAC AAT CCC TGG GCA CAA TTT TC. In primer WO265, there is an internal XhoI site (underlined) that was used in the cloning of the PCR products to the vector. The DNA was amplified in the DNA Thermal Cycler (Perkin Elmer Cetus) for 30 cycles (94°C/1 min, 62°C/1 min, 72°C/3 min). The amplified DNA fragment was gel purified and a sample of 1.5 pg (3 amol) was subjected to another round of error-prone PCR in the same conditions. Finally, the product of the second PCR was also gel purified. The products of the first and the second PCR were separately cloned back into the vector using the XhoI and BstEII restriction sites. While the mutation rates in the preliminary experiments turned out to be too high for library construction, a second round of PCR was carried out, using considerably higher amounts of initial template, i.e. 1 and 10 ng (0.3 and 3 fmol). The conditions were essentially the same as described above, except that only 25 programmed cycles instead of 30 were used and the primer WO265 was replaced by primer WO 375 (TCA CAC AGG AAA CAG CTA TGA C), which anneals to a site upstream of WO265. The upstream primer was used in order to increase the efficiency of restriction enzyme cutting and cloning, as the error-prone PCR products may have ragged ends.
Calculation of the mutation rate and the number of effective duplications
The mutation rates were determined by sequencing a stretch of 251 to 369 bases from each mutant clone and dividing the number of mutations observed by the number of nucleotides sequenced.
The number of effective duplication cycles was calculated by the following formula: ln(A) n ϭ ln (2) where n is the number of duplications and A is the amplification factor in the PCR reaction. The amplification factor A is defined as the ratio of the molar amount of product to the molar amount of initial template. The amount of DNA in each PCR product was estimated by running samples on agarose gels and comparing band intensities to known DNA standards.
Preparation of the phage display library
The error-prone PCR products and the plasmid 57-2/pComb3 were cut with XhoI and BstEII, and the fragments of 402 and 4840 bp, respectively, were gel purified and ligated at a vector/ insert ratio of 1:3. The ligation mix was ethanol precipitated, dissolved in TE buffer and electroporated in three aliquots of 0.5 µg into 50 µl XL-1 Blue cells (Stratagene). After the pulse, the cells were immediately resuspended in 10 ml SOC medium, transferred to a 100-ml Erlenmeyer flask and incubated for 1 h at 37°C with gentle shaking (225 r.p.m.). After this period, samples of the culture were diluted and plated on LA plates containing ampicillin (100 µg/ml) and tetracycline (10 µg/ml), to calculate the size of the library. Ampicillin (50 µg/ml) and tetracycline (10 µg/ml) were added to the liquid culture which was then continued at 37°C, 300 r.p.m. One hour later, a second addition of ampicillin to a final concentration 100 µg/ml was made. After another hour, helper phage VCSM13 (1ϫ10 10 p.f.u.) was added, and the phage was allowed to infect the cells for 30 min at the same cultivation conditions. The 10-ml culture was then inoculated in 250 ml SB medium containing ampicillin (100 µg/ml) and tetracyclin (10 µg/ml). This was incubated for 2 h at 37°C, 300 r.p.m. Kanamycin (70 µg/ml) was added, and the cultivation was continued for 18 h at 30°C, 300 r.p.m. The phage particles were then purified from the cell supernatant by double PEG precipitation (Sambrook et al., 1989) and resuspended in 3 ml TSA-BSA. Phage titers were determined in duplicate.
DNA sequencing
Sequencing reactions were performed with the AutoRead Sequencing Kit (Pharmacia Biotech, Sweden) according to the manufacturer's instructions, using Fluore-dATP as the labelled nucleotide and double-stranded plasmid DNA as the template. Gel electrophoresis of the reaction products and base calling were carried out with the Automated Laser Fluorescent (A.L.F.™) DNA Sequencer (Pharmacia Biotech).
Steroids and their derivatives
Structures of the steroids used in this study are shown in Figure 2 . 17β-Estradiol [1,3,5(10)-estratriene-3,17β-diol) and testosterone (4-androsten-17β-ol-3-one) were purchased from Sigma Chemical Company (St Louis, MO). Estradiol-biotin conjugate was synthetized as follows: 6-oxoestradiol 6[O-(6-aminohexyl)oxime] (Mikola and Hänninen, 1992) was coupled to N-succinimidyl ester of N-biotinyl-6-amidocaproic acid (Sigma) in pyridine-water-triethylamine (90:15:1; v/v/v) solution. The product was purified by thin layer chromatography using methanol-chloroform (3:7; v/v) as eluent. Europiumlabelled estradiol was synthetized from 6-oxoestradiol 6[O-(6-aminohexyl)oxime] (Mikola and Hänninen, 1992) and the Europium chelate of 4-[2-(4-aminophenyl)ethynyl]-2,6-bis{[N,N-bis(carboxymethyl)-amino]methyl}pyridine (Takalo et al., 1993 (Takalo et al., , 1994 using water soluble carbodiimide as condensation agent in a buffer-dioxane solution and purified on a gel filtration column using the methods of Mikola and Miettinen (1991) and Mikola et al. (1993) . Panning All panning steps were carried out at room temperature in wells of non-coated microtitration strips (PolySorp, Nunc, Denmark) which were pre-treated with the panning buffer PB (50 mM Tris-HCl pH 7.75, 0.9% NaCl, 0.05% NaN 3 , 0.01% Tween 40, 0.05% bovine γ-globulin, 20 µM DTPA, 0.5% BSA, 145 20 µg/ml Cherry Red). Phage stocks were diluted in PB and 2ϫ10 9 t.f.u. (100 µl) were added to the microtitration wells. The phage were pre-panned for 15 min with 20 µl of prewashed magnetic beads (M-280 Streptavidin, 10 mg/ml, Dynal, Oslo), after which the phage suspension was transferred to a new microtiter well for the actual panning experiment. Estradiol-biotin conjugate solution was added to the phage suspension to a final concentration of 10 nM, followed by incubation in a shaker for 60 min. When testosterone (the competitor) was present in the panning, it was mixed with the estradiolbiotin solution prior to contact with the Fab-phage. The Fabphages bound to the estradiol-biotin were captured by the addition of 10 µl magnetic beads and shaking for 10 min. The beads were collected with the magnet, and washed 5 times with the washing buffer (0.9% NaCl, 5 mM Tris-HCl pH 7.75 and 0.05% Tween 20).
Amplification of the panned phage
After the final wash, the beads were gently mixed with 200 µl of fresh XL-1 Blue cells (OD 600 0.8-1.0, grown in SB medium with tetracycline 10 µg/ml) and incubated together for two hours at room temperature with slow shaking. The cells (together with the beads) were then transferred to 2 ml SB medium containing 10 µg/ml tetracycline and shaken at 37°C, 300 r.p.m., for 1 h, after which 2ϫ10 10 p.f.u. of the helper phage was added. The helper infection was continued for 5 min before the cells were inoculated in 20 ml SB medium (10 µg/ml tetracycline and 100 µg/ml ampicillin) in a 100-ml Erlenmeyer flask. The flask was shaken at 30°C, 300 r.p.m., for 2 h, after which kanamycin was added to a final concentration of 70 µg/ml. The growth was continued for 16-20 h until the cells were approaching the stationary phase. The phage were isolated by double PEG precipitation and finally resuspended in 500 µl TSA-BSA (50 mM Tris-HCl pH 7.75, 0.9% NaCl, 0.05% NaN 3 , 10 mg/ml BSA). The phage stocks were stored at 4°C.
Removal of gene 3 fragment and production of soluble Fab
After the last round of panning, double-stranded phagemid DNA was isolated and digested with the restriction enzymes SpeI and NheI. The large fragment was gel-purified, selfligated and transformed into XL-1 Blue cells. The resulting clones, now lacking the gene 3 fragment ( Figure 1E ) were grown in SB medium containing 100 µg/ml ampicillin, 10 µg/ ml tetracycline and 10 mM MgSO 4 at 37°C, 300 r.p.m. until an OD 600 of 0.8 was achieved. After induction with 100 µM IPTG the culture was grown for additional 4.5 h at 30°C, 240 r.p.m. The cells were harvested by centrifugation (4000 g, 4°C, 15 min) and resuspended in 1/5 volume of ice-cold lysis buffer (100 mM Tris-HCl pH 8.0, 20% sucrose, 10 mM EDTA). Freshly dissolved lysozyme was added to a final concentration of 5 µg/ml and the cells were allowed to stand on ice for 15 min. The spheroplasts were separated by centrifugation (4000 g, 4°C, 15 min) and the supernatant was recovered as the periplasmic fraction. The periplasmic Fab was diluted with an equal amount of loading buffer (50 mM Tris-HCl pH 7.8, 150 mM NaCl, 0.02% NaN 3 ), filtered through 0.22 µM Millex-GV units (Millipore) and loaded on a 1-ml HiTrap Protein G column (Pharmacia Biotech) at a flow rate of 1 ml/min. The column was washed with 6 volumes of loading buffer, after which Fab was eluted with 100 mM glycine-HCl buffer, pH 2.5, containing 0.01% Tween 20, at a flow rate of 0.5 ml/min. Fractions (1 ml) were collected in Eppendorf tubes that contained 30 µl neutralization buffer (2 M Tris-HCl pH 9.0, 0.33% BSA). Assays of the fractions revealed that the recovery of immunoreactive Fab was Ͼ95%. The Fab-containing fractions (3-4 ml) were pooled and stored at 4°C. Fab determination Fab concentrations were determined with a time-resolved immunofluorometric microplate assay, using the proteolytic Fab fragment of the original monoclonal antibody 57-2 (Pajunen et al., 1997) as the calibration standard. The samples and the standards were diluted in Delfia™ assay buffer (Wallac, Finland), and were added to rabbit anti-mouse IgG-coated microtitration strips (Wallac), 200 µl per well. After shaking for 60 min at room temperature, the strips were washed four times and 200 µl of Europium-labelled E2 (2 nM) was added to each well. The incubation was continued for 60 min, after which the strips were washed four times and 200 µl of Delfia Enhancement solution (Wallac) was added. After shaking for another 30 min the Europium fluorescence was measured with the Plate Fluorometer (Model 1232, Wallac), controlled by the Multicalc immunoassay program (Wallac) running on a personal computer. The program automatically produced a spline-fitted standard curve and calculated the unknown Fab concentrations. IC 50 and cross-reactivity determinations For the IC 50 values, competitive fluoroimmunoassay was used. E2 and TES were serially diluted in a solution of Europium-146 labelled estradiol to give a range of 0 to 10 000 nM final concentration of the unlabelled steroid and a fixed concentration (0.3 nM) of the labelled estradiol. Each member of the series was then assayed for binding to the Fab fragment to be tested. The Fab sample (10 ng/ml in Delfia assay buffer) was dispensed in rabbit anti-mouse IgG-coated microtitration strips (Wallac), 200 µl per well. The strips were shaken for 2 h at room temperature, after which they were washed 4 times. The labelled and unlabelled steroid mixture (200 µl) was then added to the wells and incubated for 2 h, followed by four washes. Enhancement solution was added, and the strips were shaken for another 30 min. The signal was read with the plate fluorometer as above. As the signal from the bound Europiumlabelled estradiol decreased with increasing concentration of the unlabelled steroid, a descending dose-response curve with respect to the concentration of the unlabelled steroid was produced. The IC 50 value was defined as the concentration of the unlabelled steroid that produced a 50% decrease in the signal as compared with the zero-dose signal (B 0 ). Calculation of the IC 50 value was carried out using the spreadsheet Excel 5.0 (Microsoft) by logit transformation of the dose-response curve (Wood and Sokolowski 1981) . In brief, the logit (B/B 0 ) was plotted against the logarithm of the unlabelled steroid concentration, thus producing a straight line, whose intercept on the abscissa is log(IC 50 ).
TES cross-reactivities (CR) of the Fab fragments were calculated by dividing the IC 50 for E2 by the IC 50 for TES. Fig. 3 . Dependence of the mutation rate on the number of effective cycles. The V H region of the antibody 57-2 was subjected to error-prone PCR as described in Materials and methods. The amount of initial template was varied to achieve differences in the number of effective duplications. The PCR products were cloned into the vector pComb3 and four clones from each amplification reaction were sequenced to determine the mutation rate (i.e. number of mutations per 100 residues). Each data point in the plot represents the average of four clones originating from the same PCR reaction. Open circles, percent amino acids changed; filled circles, percent nucleotides changed.
Results
Adjustment of mutation rate
PCR usually reached a plateau at the product level of 0.5-1 µg DNA per 100 µl reaction, thus the amplification factor was mainly determined by the initial amount of template. Four different initial amounts of template were used in the errorprone PCR reactions, such that the calculated number of duplications to approach the plateau level was either 8.1, 11.4, 18.4 or 36.8, the last mentioned being the combined number of duplications in two successive PCRs, where part of the first PCR product was used as template in the second PCR. Mutation rates were determined by sequencing four clones from each PCR and calculating the percentage of mutated residues both at the nucleotide level and amino acid level. The plot of the mutation rate against the number of duplication cycles ( Figure  3 ) exhibited a linear dependence, thus the mutation rate per duplication cycle was calculated by linear regression, and was found to be 0.35 Ϯ 0.07% for amino acid changes and 0.15 Ϯ 0.02% for nucleotide changes. The randomness of nucleotide mutations was assessed by two diagnostic ratios of different types of base substitutions. In a total of 5229 sequenced bases, the ratio of transitions to transversions was 0.85 (52/61) and the ratio of AT→GC to GC→AT mutations was 2.1 (35/17).
Composition of the phage display library
The library was constructed from the products of two errorprone PCR reactions whose mutation rates were 3.6 and 1.7% at the amino acid level and 2.0 and 1.0% at the nucleotide level, respectively. The PCR products were separately cloned into vector and transformed into bacteria, yielding~1ϫ10 6 transformants each. Separate phage stocks were prepared and titered before the final pooling at equal proportions, resulting in a library of approximately 2ϫ10 6 independent clones, with an average of 2-4 amino acid changes in the 117-amino acid V H region. 
Competitive panning
The use of TES as a competing ligand effectively inhibited phage binding in the first round, as shown in Figure 4 . Outputs were 10 and 2% that of the positive control, for the 2 and 10 µM TES, respectively. More stringent conditions were not used, since the background control (i.e. no biotinylated antigen present) gave an output of 1-2%. During successive panning cycles, the relative outputs gradually increased, approaching 40 (2 µM TES) and 80% (10 µM TES) of the positive control, indicative of the enrichment of mutants that are less crossreactive to testosterone. Changes in testosterone cross-reactivity After the fourth panning round, the phagemid DNA was isolated and the gene 3 fragment was deleted (Figure 1 ), as originally described by Barbas et al. (1991) . Twelve clones were randomly picked from both lineages for the analysis of mutations and binding characteristics. The clones denoted A1-A12 were obtained from the panning with 2 µM TES, while clones B1-B12 were obtained with 10 µM TES. The IC 50 values for E2 and TES as well as the cross-reactivities are presented in Table I .
Analysis of the mutants shows that the increase in the relative outputs observed in the panning rounds arises mainly from the increase in the IC 50 for TES. The mean IC 50 of series A mutants (panned in the presence of 2 µM TES) had increased 12-fold while that of series B mutants (panned in the presence of 10 µM TES) had increased as much as 25-fold (Table I) . The higher average IC 50 for TES among the series B mutants is in accordance with the high outputs in the fourth round of panning under stringent selection pressure (Figure 4 ). Affinity to E2 has changed little in either series: the IC 50 ranges from 0.6-to 2.4-fold relative to the wild type.
Distribution of mutations
After nucleotide sequencing of the V H regions of the mutant clones, the deduced amino acid sequences were compared with the wild-type sequence and to each other (Table I) . Some of the clones turned out to be identical with each other, even at a The CDR definitions and residue numbering are according to Kabat et al. (1991) . the nucleotide level. These clones [A2/A8; A5/A11; A10/B7, Bx (B1-B4, B6, B8-B12)] are shown only once. As expected, also the binding properties (IC 50 for E2 and TES) were identical within each such group.
Apart from the occurrence of identical groups and pairs, there are 13 independent clones (A10 and B7 coming from separate lineages), comprising a total of 35 amino acid changes (Table I ) plus 20 silent mutations. All but one of the amino acid changes are single nucleotide mutations. The only exception is the S32P found in the group Bx, where the codon TCT is mutated to CCA. However, the last nucleotide of the triplet is not significant both for the serine and the proline codons. Consequently, the selected mutants do not include cases where multiple mutations in the same codon are required to produce the changed amino acid residue.
The mutations are strongly centered to CDR1 and CDR2: every clone contains mutations in one of the two hot spots, located around Ser32 and Thr52 A , respectively. In contrast, CDR3 is totally lacking mutations. The remaining mutations in the framework regions are unevenly distributed as well; there are three hits at Tyr27 and two hits at Met30 and Glu72, respectively.
Discussion
Error-prone PCR as a mutagenesis method
The error-prone PCR, pioneered by Leung et al. (1989) , couples the intrinsic low fidelity of the Taq polymerase with reaction conditions that favour the misincorporation of wrong nucleotides. While the original protocol generated considerably more AT to GC than GC to AT mutations, Cadwell and Joyce (1992) developed an appropriately balanced nucleotide mixture 148 that compensated for this effect. Using the preferred dNTP mixture as suggested by Cadwell and Joyce (1992) , we obtained a reasonably random distribution of mutations. In order to use error-prone PCR as a general random mutagenesis tool, we aimed at a reproducible method to generate a pre-determined number mutations to the target region. As it is obvious that the overall mutation rate depends on the number of template duplications in the PCR reaction, this dependence was not previously exactly defined. We therefore experimentally determined the mutation rates resulting from different amounts of initial template in the error-prone PCR. The results show that there is a simple linear dependence between the mutation rate and the number of template duplications (Figure 3) , which is consistent with a model in which mutations accumulate at a constant rate in each duplication cycle. Knowing the average mutation rate per duplication, it is easy to adjust the initial amount of template so that a pre-determined number of mutations will be achieved as the plateau phase is reached.
As the error-prone PCR operates at the nucleotide rather than the codon level, there are differences in the relative propensities of the resulting amino acid changes depending on how many base changes are needed. At the mutation rate of 1% per base, the rate per codon is 2.94% for single base changes, 0.0297% for double base changes and 0.0001% for triple base changes. Therefore the outcome of the selection experiments must be interpreted in the light of this initial bias. Any mutations that require two or three base changes in the same codon must compete with the single-base mutations that occur at much higher frequency, and will be picked out only if they possess a strong selective advantage in the panning rounds. In practice, the error-prone PCR library may be regarded as a source of amino acid point mutations that arise from single base changes. How this affects the scope and reach of the method, will be discussed below.
Dynamics of the panning process
Starting out with the assumption that most of the random mutations were neutral with respect to TES cross-reactivity, we aimed at a selection stringency that would decrease the recovery of this vast majority of the mutants near to the background level. The useful range for the competitor concentration was estimated in preliminary panning experiments using europium-labelled wild-type Fab fragments instead of phages (not shown). In those experiments, 2 µM and 10 µM TES inhibited the binding of the labelled Fab fragment to the biotinylated antigen down to a level of 10 to 2% of the positive control reaction, respectively. Using the same TES concentrations in the actual pannings, we obtained remarkably similar results (Figure 4, first panning round) . This supports the assumptions that (i) the majority of the mutant clones in the initial population were unaltered with regard to TES crossreactivity and (ii) Fab fragments displayed on the phage particles behave like independent soluble Fab fragments when an appropriate panning configuration is used. Here, the selective reaction (competition between TES and the biotinylated E2) was carried out in solution before the rapid capture step; hence the panning outcome corresponded to the results obtained in the model experiment.
The increase of the relative outputs in the successive panning rounds is different for the low and high stringency conditions (Figure 4 ). While the high stringency level (10 µM TES) initially gives low relative outputs, it efficiently eliminates the unimproved clones, leading to a rapid increase in the relative outputs in next rounds. The low stringency level (2 µM TES) is less discriminative and produces a low but steady growth in each cycle, approaching an output level of 40% in the fourth round. At the low level of stringency, the discrimination between moderately improved mutants and the very best clones is ineffective, and it may take a great many cycles to select out the best ones. A preferred stringency level would produce relative outputs only slightly above the background in the first round, which is the case for the 10 µM TES.
The binding characteristics of the mutants isolated after the fourth round reflect the relative phage outputs achieved. Accordingly, the average TES IC 50 has increased 12-fold for the low stringency group A and 25-fold for the high stringency group B, respectively (Table II) . Because the IC 50 values for E2 have changed relatively little, the net effect in each case is a considerable decrease in the TES cross-reactivity, which was the primary goal of this study. The fact that the affinities to E2 are more or less maintained at the original level can be attributed to several factors of the panning configuration. The phagemid vector pComb3 is supposed to produce predominantly (but not categorically) monovalent phage particles (Barbas et al., 1991) that cannot bind to two adjacent antigens at the same time. This should efficiently prevent the recovery of low affinity mutants that would otherwise be captured by virtue of the avidity effect. Moreover, the avidity effect was repressed by performing the binding to the biotinylated antigen in solution before the capture step, similarly as Hawkins et al. (1992) with the distinction that they used a multivalent phage vector and thus had a more serious concern about the avidity effect. Finally, the use of a relatively low biotinylated antigen concentration (10 nM) forced the mutant clones to maintain a 149 reasonable affinity constant in order to be passed on to the next round.
The applied stringency level also had an effect on the drop of diversity, indicated by the number of identical clones obtained after the fourth round. In the low stringency series A, the mutant population was still rather diversified, as only two clones were represented twice (A2/A8 and A5/A11). By contrast, the high stringency series B was driven to almost complete homogenization; 10 of the 12 sequenced clones were identical. Obviously further rounds would have singled out the fittest clone alone, which was not the purpose here. Consequently, it is useful to monitor the panning process through the determination of the outputs for the selective conditions as well as for the background and the positive controls. The relative outputs not only reflect the enrichment rate but also predict the degree of homogenization of the phage population and thus serve as a valuable indicator of the dynamics of the panning process at different stringencies.
Identification and grouping of the key mutations
The distribution of the mutated residues along the V H region exhibits two hot spots in CDR1 and CDR2 and two minor foci in the end of FR1 and start of FR3 (Table I ). The possibility that these hot spot areas might be PCR artifacts was excluded as none of these mutations nor other clusters of mutations were found in eight sequenced mutants isolated from the original, unpanned library (data not shown). Thus the observed clustering of mutations must be due to selective enrichment during the panning rounds. Every clone is mutated in either CDR1 or CDR2 while no one contains mutations in both at the same time. Therefore, we will discuss the clones as two groups according to the CDR mutations.
The CDR1 group is delineated by two prototype clones, A3 and A10/B7, which do not contain amino acid replacements elsewhere in the V H region. In these clones, the altered binding properties can be unambiguously attributed to the CDR1 mutations. Interestingly, the same mutations are also found in two multiply mutated clones, which makes it possible to evaluate the significance of the accompanying mutations. In the case of the prototype clone A3 (mutation S32Y), the TES cross-reactivity has decreased by a factor of 4.0 while with the multiple mutant A1 (S32Y, A68S, S113T), the factor is 4.4. Thus, here the additional mutations do not significantly influence the binding specificity. The other prototype clone A10/B7 (S32P, M34I) displays a drastic decrease in crossreactivity (18.1-fold), which is more or less maintained in its multiply mutated counterpart A4 (Y27H, S32P, M34I; 15.7-fold). The remaining clones of the CDR1 group (A7, Bx) cannot be directly compared with the prototype clones, because their CDR1 mutations are slightly different. However, as the serine at position 32 is always mutated, we may assign a major role for that residue also in the clones A7 and Bx. The mutation S32P is constantly associated with a relatively large decrease in TES cross-reactivity (about 15-20-fold), while the aromatic mutations S32Y and S32F produce only a moderate (4-6-fold) decrease.
The CDR2 group is denoted by the prototype clone A5/ A11, which contains only the single point mutation T52 A P. The same mutation is shared by the multiply mutated clones A2/A8 (T52 A P, K83Q) and B5 (M40K, T52 A P, L71S, F91Y, T108S). As before, the additional mutations bring no further advantage compared with the single mutation. On the contrary, while the decrease in TES cross-reactivity for A5/A11 is 14.7-fold, that of A2/A8 is 11.9-fold and that of B5 is 7.0-fold. Therefore, in this case, the other mutations seem to be selected merely because they happened to occur together with the advantageous key mutation T52 A P. In the clone A12 (M30L, T52 A S, G104S, S112T), the threonine 52 A is mutated to a serine instead of a proline, causing an even more pronounced decrease in the TES cross-reactivity (17.0-fold). The CDR2 loop offers a variety of opportunities to affect the crossreactivity, since also the position of the mutated residue can be shifted, as demonstrated by the clones A6 (M30K, Q53P, E72D) and A9 (Y27N, S54T, Y74V) . While the clone A6 shows an 11.8-fold and the clone A9 only a 4.1-fold decrease in TES cross-reactivity, it is premature to conclude to what extent their difference is connected to the position rather than to the character of the mutated residue. A larger set of CDR2 mutations would be required to outline the limits of mutational improvement for each position.
Interestingly, the studies on several spontaneous hybridoma mutants of the anti-digoxin antibody 26-10 reveal that the altered binding properties result in most cases from point mutations in CDR1 and CDR2 of the heavy chain (Schildbach et al., 1993a (Schildbach et al., ,b, 1994 Short et al., 1995) . According to the crystal structure of 26-10 bound to digoxin, the binding is based solely on shape complementarity, lacking any hydrogen bonds between the steroid and the antibody (Jeffrey et al., 1993) . However, the binding site residues are hydrogen bonded to each other, and mutations perturbing this architecture lead to changes in the affinity and specificity (Schildbach et al., 1994) . In the case of the antibody 57-2, the obtained crossreactivity mutations do not alter the binding to estradiol, suggesting that these residues do not form hydrogen bonds with the hapten. More likely, the mutations act by reshaping the van der Waals surface of the binding site so that TES (whose A ring differs from that of E2) does not fit in as readily as before. The mutations S32Y and S32F introduce bulky residues, while the mutations S32P, T52 A P and Q53P create a cyclic amide in the backbone leading to potentially large conformational changes in the corresponding CDR loops. The fact that these radical mutations are tolerated so well is understandable in the light of the originally poor recognition of the A ring, implying that the main interactions contributing to the binding affinity lie elsewhere and are not affected by these cross-reactivity mutations.
The sporadic secondary mutations in the framework areas are probably of less significance if not fully neutral. However, a slight clustering of mutations is seen at residues 27 and 30 in FR1 and in the vicinity of residue 71 in FR2. A closer look at these mutations reveals that they indeed can have a contribution to the binding properties. Tyrosine 27 has been independently mutated in three clones (A4, A7 and A9). In the clone A4, the effect of the Y27H mutation can be directly assessed by comparing the binding properties of A4 and the prototype clone A10/B7, since there are no other differences between the clones. The mutation Y27H shifts the IC 50 for E2 from 67 to 48 nM and the IC 50 for TES from 1548 to 961 nM, which means an increase in the affinity for both antigens. The net effect on cross-reactivity is a slight (unfavourable) increase from 4.3 to 5.0%. At first glance, the mutation Y27H in A4 seems to be just a free passenger which travels by virtue of the CDR1 mutation in the same clone. Still, the increased E2 affinity (compared with A10/B7) could be a selective advantage. The monovalent Fab display method and the relatively low concentration of the biotinylated antigen restrict 150 the recovery of low affinity mutants. As the clone A10/B7 has clearly the lowest affinity of all the clones, any increase in the affinity could be a valuable aid. Why, then, did the clone A10/ B7 survive at all after four rounds of panning? One explanation could be that the initial mutation(s) (S32P, M34I) occurred in the early PCR cycles whereas only later on one of the descendant strands acquired the Y27H mutation. As a consequence of the order of events, the majority of the clones that contain the S32P, M34I mutations do not contain the Y27H mutation. The lower fitness of the prototype clone is thus compensated by its higher initial representation in the library.
The significance of the mutation Y27N, found in the clones A7 and A9, cannot be deduced from the binding properties, because there are no matching prototype clones to compare with. Similarly, the mutations in methionine 30 (M30L in A12 and M30K in A6) and glutamate 72 (E72D in Bx and A6) are found together with CDR mutations that are not present in other clones. In fact, the lack of the corresponding pure CDR mutants suggests that the secondary mutations are necessary for the correct function of Fab. The secondary mutations could be auxiliary in the sense that they reduce the possibly negative side effects caused by the (primary) CDR mutations. It is known that residues 27-30 form part of the first antigenbinding loop (Chothia and Lesk, 1987) and consequently are able to affect its conformation. Likewise, residue 71 has been described as a major determinant of the CDR2 loop conformation (Chothia et al., 1989; Tramontano et al., 1990) . The importance of these 'Vernier' zone residues has been experimentally verified in antibody humanization experiments, where murine CDR loops were transferred to human frameworks. The antigen-binding activity could be re-established only after the change of selected human framework residues back to the murine counterparts (Foote and Winter, 1992; Tempest et al., 1995) . However, the actual significance of the FR1 and FR3 mutations found here cannot be assessed without further evidence from comparative and/or structural studies. Scope and reach of the whole domain mutagenesis Random mutagenesis of the whole variable domain is not a method for the exhaustive search of all possible amino acid mutations and their combinations, because the library size is limited in practice. Bearing this restriction in mind, the whole domain mutagenesis still has several advantages that are not achievable by other, more targeted methods. For one thing, there is no requirement for structural knowledge about the antigen-antibody interaction. Although it is known that three hypervariable loops (CDR H3, CDR L3 and CDR H2) generally dominate the overall binding interactions (Wilson and Stanfield, 1994) , one cannot be confident that any particular loop would be a profitable target for mutagenesis. For instance, we found no cross-reactivity mutations in the CDR3 loop: the lack of mutations might imply that the loop residues are not involved in contacts between the antibody and the steroid A ring (where estradiol and testosterone differ from each other). Typical of anti-hapten antibodies, the CDR3 is relatively short, six residues. If it is not protruding out of the protein, but rather serves a structural role in the V H -V L interface, the option of mutations available to it may be restricted. Our findings do not rule out the possibility that a more thorough survey of CDR3 by oligonucleotide cassette mutagenesis might still detect new cross-reactivity mutations. However, our results suggest that such an effort could be more successful if directed at CDR1 or CDR2.
Even though only a fraction of the potential diversity in the V H domain can be covered by the error-prone PCR library, there is a significant subset of the sequence space that is virtually completely represented; this subset comprises the amino acid point mutations that arise from single base changes (SBCs). The number of all possible SBCs for the V H region is as low as 1053 (there are 351 nucleotides in the V H region and each one can be mutated in three ways). As the average clone in the library contains five mutations, the probability of a particular SBC being present in a randomly picked clone is 5/1053 ϭ 0.47%. In other words, approximately one in every 211 randomly picked clones carries the particular SBC. Consequently, the whole library (totally 2ϫ10 6 clones) contains approximately 9500 copies of each SBC, although in varying contexts depending on the other mutations present in each individual clone. The subset of amino acid point mutations arising from SBCs offers 5-6 different alternative residues for each position, thus forming a good basis for the search of positions of potential interest. Where the effects of amino acid point mutations have been studied, usually several alternative mutations in the same position are able to modulate the fine specificity of the antibody (Schildbach et al., 1993a (Schildbach et al., ,b, 1994 Kussie et al., 1994; Wong et al., 1995) . This increases the probability that a key residue will be detected even if the library does not contain all of the 19 possible amino acid substitutions for the particular position. For instance, we found three different amino acid substitutions at Ser32 (Tyr, Phe and Pro); possibly these mutations are not the best ones for that position but they were those available in the SBC subset. After identifying position 32 as an important determinant of the steroid specificity, we can subsequently devise more directed libraries targeted at that position and its surroundings.
The molecular basis of steroid cross-reactivity has been studied in detail by Arevalo et al. (1993a,b; who determined the three-dimensional structures of the anti-progesterone antibody DB3 and its complexes with five crossreactive steroids. They found that the antibody-hapten shape complementarity was not complete, leaving space for modifications in the steroid structure. In all of the complexes, the D ring was inserted in the same hydrophobic cavity where a hydrogen bond was formed between the AsnH35 and the keto group of position C17 or C20, while the A ring could find two alternative binding pockets depending on the steroid. Analogously, for the antibody 57-2, the estradiol D ring seems to be buried in the binding site, because any modifications in positions 16 and 17 decrease the cross-reactivity to below 0.2% (unpublished data). On the contrary, the A ring can possess various substitutions and changes in the ring conformation without major effects on binding, which might imply that the A ring is exposed to the solvent; another possibility is the presence of alternative pockets or simply free space in the binding site like in the case of the DB3 antibody . The latter alternative is particularly attractive considering the β-methyl group at C10 of testosterone (C19, Figure 2C ). Position C10 is probably at least partially buried in the binding site, because the antibody 57-2 was originally raised with the immunogen estradiol-6-CMO-BSA (Pajunen et al., 1997) . Generally, the ring positions opposite to the linker attachment site tend to be buried as the linker itself must come out of the binding site, as shown for several progesterone antibodies by Gani et al. (1994) . If the antibody 57-2 cross-reacts with TES because there is a fortuitous pocket present in the binding site that accommodates the C19 of testosterone, there is potentially a large set of mutations that could block the pocket. The fact that we found various cross reactivity-decreasing mutations in CDR1 and CDR2 of the heavy chain supports the idea that such a pocket (or free space) could be filled by several different mechanisms at the molecular level. When there is no absolute selectivity with respect to the particular amino acid replacements, even a medium-sized library of a limited coverage can be used to isolate mutations that define the key residues.
In conclusion, we have shown that a random library of the whole variable domain, covering an assortment of 5-6 amino acid mutations for each residue, contains several mutants of improved specificity. By comparative sequence analysis, it is possible to identify the residues conferring the improved binding properties even in the presence of multiple irrelevant mutations. The key residues can then serve as 'leads' for the creation of more complete targeted libraries as well as for the creation of combinatory libraries by the parsimonious mutagenesis strategy (Balint and Larrick, 1993; Schier et al., 1996) .
